BioSpace News Archive

Daxor Corporation announced that the National Institutes of Health National Institute of General Medical Sciences has awarded the Company a $305K Phase I Small Business Innovative Research grant to support the development of the Sepsis FLO, a clinical decision support tool designed to precisely guide blood volume management and treatment in sepsis patients.

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the Baader Investment Conference 2023 in Munich to be held from September 18-21, 2023.

Dr. Charles E. Runels Jr., M.D., the President of Cellular Medicine Association, Inc. (“CMA”), has now applied for registration of the trademark PRIAPUS TOXIN™ for “medical services, namely, injecting the corpus cavernosi of the penis with therapeutic neurotoxins to improve penile health and to enhance erectile function or penis size.”

Black Diamond Therapeutics, Inc. today announced the first patients dosed in mutation matched expansion cohorts of non-small cell lung cancer in the ongoing Phase 1 clinical study evaluating BDTX-1535.

Biora Therapeutics, Inc today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.

Ardelyx, Inc. shared encouraging data on IBSRELA ® (tenapanor) via two poster presentations presented at the 2023 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference currently being held in National Harbor, Maryland September 7-9.

Limaca Medical (“Limaca”) announced today that its Precision GI™ Endoscopic Ultrasound (EUS) Biopsy Device received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”). This follows Limaca’s receipt of FDA Breakthrough Device Designation for its Precision GI™.

Oxular Limited , a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announces that Mark Gaffney has been appointed as chief executive officer (CEO) and member of the Board of Directors.

BioMarin Pharmaceutical Inc. will update the investor community on the company’s research and development portfolio, including early-stage product candidates and new indication opportunities with VOXZOGO and ROCTAVIAN.

Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America, Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced today that the Phase 3 URO-901-3005 clinical study of vibegron.